EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the ...
Fintel reports that Deep Track Capital has filed a 13G/A form with the SEC disclosing ownership of 2.66MM shares of 4D Molecular Therapeutics Inc (FDMT). This represents 8.2% of the company. In their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback